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Fanconi anemia is characterized by hypersensitivity to DNA interstrand crosslinks (ICLs) 
and susceptibility to tumor formation. Despite the identification of numerous Fanconi 
anemia (FANC) genes, the mechanism by which proteins encoded by these genes protect 
a cell from DNA interstrand crosslinks remains unclear. The recent discovery of two DNA 
helicases that, when defective, cause Fanconi anemia tips the balance in favor of the direct 
involvement of the FANC proteins in DNA repair and the bypass of DNA lesions.Fanconi Anemia
Fanconi anemia (FA) is a rare, recessive (autosomal or 
X-linked) chromosomal-instability disorder, character-
ized by a striking hypersensitivity to DNA interstrand 
crosslinks (ICLs). The disease is clinically highly hetero-
geneous, even between monozygotic twins (Auerbach 
and Allen, 1991; Auerbach et al., 2001; Kook, 2005), 
which dramatically complicates diagnosis. FA may be 
evident at birth due to congenital anomalies includ-
ing aplasia of the thumb or radii and abnormal facies. 
Given that FA is linked with an increase in spontane-
ous chromosomal aberrations and cell death, these 
congenital anomalies are probably caused by such sto-
chastic events in critical progenitor cells early in devel-
opment. In some cases, FA may only become evident 
in early childhood due to renal dysfunction, abnormal 
pigmentation, and short stature, or the diagnosis may 
be made in adulthood due to the early onset of can-
cer. A hallmark feature of FA is pancytopenia (median 
age at onset 7 years) due to increased apoptosis of 
hematopoietic cells. The genomic instability of the sur-
viving cells leads to myelodysplastic syndrome and 
acute myeloid leukemia (800-fold increased risk), with 
14 years as the median age of onset (Kook, 2005). The 
risk of developing solid tumors is also increased, in par-
ticular squamous cell carcinomas of the mucosal epithe-
lia and liver tumors (Kook, 2005). Although the median 
survival of FA patients is 16 years, the survival range 
is wide. Complications of bone-marrow failure are the 
most common cause of death (Alter et al., 1991; Kook, 
2005). The early onset of cancer is a common feature 
of FA and is attributable to chromosomal instability. In 
addition, there is likely to be an accelerated aging com-
ponent of FA caused by increased cell death in the pro-
liferative compartments of the body, which leads to, for 
example, depletion of hematopoietic reserves.From Cellular Studies to Extreme Genetic  
Heterogeneity
The hypersensitivity of cells from FA patients to DNA ICL 
agents (such as mitomycin C or diepoxybutane) is the basis 
for the diagnosis of FA. ICLs are a particularly deleterious 
type of DNA lesion because they covalently tether both 
strands of the DNA helix together. This prevents strand sep-
aration, an obvious prerequisite for vital cellular processes 
such as DNA replication and transcription. As a result, ICLs 
are extremely cytotoxic, particularly for proliferating cells. 
Hence, crosslinking agents are among the most effective 
cytotoxic drugs used in cancer chemotherapy. The fact 
that FA cells are hypersensitive to this type of DNA dam-
age suggests that individuals with FA have defects in ICL 
repair. However, increased sensitivity could also arise from 
abnormalities in (1) complex mechanisms to tolerate ICLs 
rather than repairing them (such as replication bypass), (2) 
the cell-cycle-control machinery, (3) mechanisms of apop-
tosis, or (4) metabolic inactivation of crosslinking agents. 
In addition, cells from FA patients are modestly sensitive 
to other types of DNA damage (such as ionizing radiation 
and oxidative stress), and FA proteins are activated in S 
phase of the cell cycle (Taniguchi et al., 2002), suggesting 
a more general role in the DNA-damage response. Thus, 
the precise nature of the cellular processes affected in FA 
is unresolved.
In all cells, replication of DNA containing ICLs induces 
double-strand breaks (DSBs) (De Silva et al., 2000; Nie-
dernhofer et al., 2004). ICLs are also potent inducers of sis-
ter-chromatid exchange (SCE), suggesting that these rep-
lication-dependent DSBs are frequently resolved through 
the production of SCEs (Figure 1). SCE represents the 
reciprocal exchange of the DNA strands between identical 
sister chromatids and thus only occurs during or after DNA 
replication. Not surprisingly, SCE requires the homolo-
gous-recombination machinery (Sonoda et al., 1999). Dur-Cell 123, December 29, 2005 ©2005 Elsevier Inc. 1191
ing DNA repair, homologous recombination allows the DNA 
at a broken sister-chromatid end to pair with the identical 
sequence of the other sister chromatid, using this sister as a 
template for the synthesis of lost genetic information (Helle-
day, 2003). During this intricate DNA gymnastics, cross-
over can occur, resulting in the exchange of DNA strands 
between the two sister chromatids. Importantly, DSBs in 
DNA that yield two broken ends (such as those caused 
by ionizing radiation), which can be directly recombined 
with one another, generally do not induce SCEs (Helleday, 
2003). However, collapse of a replication fork results in only 
one broken double-strand end (for structure, see Figure 2). 
These single DSBs that arise in S phase are more likely to 
stimulate SCE (Helleday, 2003). These observations imply 
a role for DNA replication, replication-induced DSBs, and 
the subsequent repair of these DSBs by 
homologous recombination in the repair 
of ICLs.
In addition to SCEs, a small fraction 
(<5%) of cells treated with a crosslink-
ing agent also contain a radial structure 
(Figure 1). Radial structures are created 
when broken sister chromatids of dispa-
rate chromosomes become erroneously 
fused to one another, creating a tandem 
array of chromosomes connected via 
recombined sister chromatids (Figure 
1). Radial-structure formation, like SCE, 
requires DNA replication and DSBs. 
Apparently, they arise if homologous-
recombination-mediated repair of the 
DSBs does not occur and instead the 
DSBs are repaired through illegitimate 
recombination—for example by single-
strand annealing, in which broken ends 
with only small regions of sequence 
homology are joined.
The frequency of SCE in response to crosslinking agents 
is normal in FA (Mosedale et al., 2005; Niedzwiedz et al., 
2004); however, the number of radial structures increases 
dramatically. Multiple radial structures occur in 30%–100% 
of FA cells treated with crosslinking agents, which is the 
diagnostic criteria for FA (Kook, 2005). This implies that FA 
cells are defective in homologous-recombination-mediated 
repair of DSBs induced by ICLs (Figure 1). Alternatively, the 
cells may be defective in a cell-cycle checkpoint that per-
mits safe repair of ICLs before reentry into the cell cycle or 
in some other mechanism of handling ICLs during replica-
tion. With respect to the last possibility, FA cells intriguingly 
show a lower frequency of point mutations (single-base-
pair changes) than normal cells, in striking contrast to their 
Figure 1. Chromosomal Changes that Can 
Occur in Response to DNA-Interstrand-
Crosslink Damage
In a cell without DNA damage, DNA replication du-
plicates each chromosome during S phase to cre-
ate sister chromatids. Newly synthesized strands 
of DNA are indicated in light gray. If the chromo-
somal DNA contains a DNA interstrand crosslink 
(ICL, blue bar), replication is blocked, resulting in 
the creation of a DSB. In normal cells, this DSB is 
repaired by homologous recombination, frequently 
resulting in sister-chromatid exchange (see text 
for details and Figure 2 for mechanism). Typically, 
ICL repair leads to the creation of a mutation (gold 
bar) at or near the site of the ICL. Inset: On rare 
occasion (<5%) in normal cells, the ICL-induced 
DSB is not repaired by homologous recombination 
and persists (chromatid break). These DSBs can 
then be eliminated by illegitimate recombination 
with nonhomologous sequences on other chro-
mosomes, yielding radial structures (chromatid fu-
sions). In FA patients, treatment with DNA-damag-
ing agents that induce ICLs results in 30%–100% 
of the cells in the patient showing multiple chroma-
tid breaks and radial structures due to increased 
frequency of illegitimate recombination.1192 Cell 123, December 29, 2005 ©2005 Elsevier Inc.
elevated chromosomal instability. This indicates that, nor-
mally, the intact FA pathway induces point mutations while 
preventing chromosome aberrations. This is consistent 
with a mechanism that involves the bypass of a DNA lesion 
(which has a high chance of creating point mutations) in 
the FA pathway to repair ICLs. This is supported by genetic 
data demonstrating that error-prone translesion polymer-
ases act in the FA pathway (Niedzwiedz et al., 2004).
Confusingly, cells from FA patients are not inherently 
defective in homologous recombination, as demonstrated 
by their capacity to trigger SCE (Mosedale et al., 2005; 
Niedzwiedz et al., 2004), their relatively mild sensitivity to 
ionizing radiation (Bridge et al., 2005; Niedzwiedz et al., 
2004), and their ability to accurately repair a DSB created 
by a restriction endonuclease (Nakanishi et al., 2005). 
Thus, if DNA repair is affected in FA, the defect is likely 
limited to a special subset of lesions (most notably ICLs) 
that induce replication stress. Alternatively, other findings 
point to impaired cell-cycle control in FA. Rather than halt-
ing DNA replication during S phase to permit ICL repair, 
FA cells continue DNA synthesis (Sala-Trepat et al., 2000), 
risking creation of DSBs at sites of damage. In support of 
this, spontaneous chromosomal breaks are more common 
in FA cells than in wild-type cells. This is highly reminiscent 
of another chromosomal-instability disorder, ataxia telangi-
ectasia, in which DNA replication is not delayed in response 
to radiation-induced DNA damage. ATM, the protein defec-
tive in this disorder, is a transducer in a complex signaling 
cascade in response to DSBs (Kurz and Lees-Miller, 2004). 
In fact, one of the FA proteins (FANCD2) is an effector of 
ATM required for the DNA-damage checkpoint in S phase 
(Taniguchi et al., 2002). In contrast to S phase, the G2 
checkpoint is intact in FA cells (Sala-Trepat et al., 2000). 
Thus, after exposure of FA cells to genotoxic stress, the 
majority of the cells collect in G2. In fact, G2 is prolonged in 
FA cells that have not been exposed to stress compared to 
normal cells, apparently in response to persistent endog-
enous DNA damage.
The phenotypic heterogeneity of this syndrome spawned 
a search for multiple genetic causes of FA that could be 
responsible for the extreme clinical variation. This search 
was facilitated by the exquisite sensitivity of FA cells to 
ICLs, which allowed for the identification of distinct com-
plementation groups (each complementation group repre-
sents FA patients with defects in the same gene). Such 
complementation groups can be identified when cells 
(such as fibroblasts or lymphoblastoid cells) from different 
patients are fused together and the resulting cell popu-
lation is screened for wild-type resistance to ICL dam-
age by the complementation of each other’s defect. This 
endeavor proved highly rewarding. The total number of FA 
complementation groups has now risen to 12 (FANCA, B, 
C, D1, D2, E, F, G, I, J, L, and very recently M; see below), 
with more to come. Curiously, this genetic heterogene-
ity does not explain the clinical heterogeneity, although a 
systematic analysis of a possible link between individual 
complementation groups and specific clinical manifesta-
tions is warranted.From Gene Cloning to Function
The expectation that cloning the genes defective in each of 
the complementation groups would reveal an FA pathway 
turned out to be false. Sequence analysis of the first series 
of FA genes isolated did not yield any meaningful homol-
ogy to other proteins or hints about protein function. With 
FANCI still awaiting identification, only 4 of the 11 cloned FA 
genes have provided clues about the functions of the pro-
teins they encode. This includes FANCD1, which is identi-
cal to BRCA2, the breast cancer susceptibility gene impli-
cated in homologous recombination (Howlett et al., 2002); 
FANCL, which encodes an E3 ubiquitin ligase implicated in 
the monoubiquitination of FANCD2, an essential step in the 
FA pathway (Meetei et al., 2003a); and the latest additions: 
FANCJ and M, both encoding DNA helicases.
Nearly all of the FA proteins physically interact in the cell, 
comprising an FA core complex (Garcia-Higuera et al., 
2001; Meetei et al., 2003a; Meetei et al., 2004). This com-
plex includes FANCA, B, C, E, F, G, and L, together with 
as yet uncharacterized additional components (Meetei et 
al., 2005). In S phase, FANCL monoubiquitinates FANCD2, 
a process that also requires FANCI (which is not part of 
the core FA complex). This in turn triggers association of 
FANCD2 with chromatin and its accumulation in nuclear 
foci. These foci are thought to demarcate the sites where 
DSB repair and replication bypass of DNA damage occurs. 
Activated FANCD2 colocalizes with factors involved in 
homologous-recombination-mediated DSB repair such 
as BRCA1, BRCA2/FANCD1, and RAD51 (Taniguchi et al., 
2002). RAD51 forms a nucleoprotein filament on broken 
DNA ends, searches for the homologous sequence in the 
sister chromatid, and catalyzes strand exchange required 
for homologous recombination. Also, replication factors 
such as PCNA and RPA are present in these nuclear foci. 
The FA core complex itself is required for translocation of 
FANCD2 to these nuclear foci, even after monoubiquitina-
tion is complete, and subsequently for the nuclear foci to 
restore replication and cell-cycle progression (Matsushita 
et al., 2005). The FA core complex also interacts with the 
BLM-TOPOIIIα complex (Meetei et al., 2003b). This com-
plex is involved in the proper dissolution of double Holli-
day junctions, intermediates of homologous recombination 
(Wu et al., 2005). Now, the newest FA proteins, FANCJ and 
FANCM, can be added to the FA pathway.
Identification of FANCJ
Single-nucleotide polymorphism analysis of FANCJ families 
pinpointed a region on chromosome 17q22 containing the 
culprit gene. Sequencing of candidate loci identified bial-
lelic mutations in a gene called BRIP1 (BRCA1-interacting 
protein 1) or BACH1 (BRCA1-associated C-terminal heli-
case 1) in multiple families from the FANCJ complementa-
tion group (Levitus et al., 2005; Levran et al., 2005). The 
link with FA was independently made in chicken lympho-
blast DT40 cells, in which inactivation of the chicken ortho-
log of BRIP1 yielded an FA-like phenotype with extreme 
sensitivity to ICL damage (but not to UV, ionizing radiation, 
hydrogen peroxide, or alkylation damage) and arrest in Cell 123, December 29, 2005 ©2005 Elsevier Inc. 1193
late S/G2 in response to ICL damage (Bridge et al., 2005). 
Ubiquitination of FANCD2 is normal in these cells, indicat-
ing that FANCJ acts downstream of this key event in the 
FA pathway. Cells deficient in both FANCJ and FANCC are 
more sensitive to ICL damage than cells with a mutation in 
just one of these FANC proteins, suggesting that the two 
proteins may participate in redundant DNA-repair path-
ways (Bridge et al., 2005). Similar results were obtained in 
human cells using small interfering RNAs (siRNAs) to knock 
down expression of BRIP1/BACH1. These cells showed 
accumulation of ICL-induced chromatid breaks and radial 
structures, as well as γH2AX and RAD51 foci (indicative of 
DSBs), but normal FANCD2 ubiquitination in response to 
ICL damage (Litman et al., 2005). FANCJ encodes a 5′→
3′ helicase that interacts with the BRCT repeats of BRCA1, 
which mediates colocalization of the two proteins in late 
S/G2 (Cantor et al., 2001). Furthermore, repair of radia-
tion-induced DSBs is retarded in cells expressing an inac-
tivated FANCJ helicase (Cantor et al., 2001), suggesting a 
direct role for this protein in DNA repair. The recombinant 
human FANCJ helicase preferentially binds to and unwinds 
forked duplex structures but not duplexes with a single-
strand overhang or Holliday junction cruciform structures 
(Gupta et al., 2005). FANCJ executes efficient strand dis-
placement from a D loop substrate, which represents a 
likely intermediate in homologous recombination. Thus, it 
is logical to position the FANCJ helicases in the FA pathway 
downstream of FANCD2 monoubiquitination, the creation 
of ICL-induced DSBs, and formation of damage-induced 
nuclear foci.
Identification of FANCM
Using mass spectrometry, a 250 kDa protein that coim-
munoprecipitated with the FA core complex was identi-
fied as the human ortholog of archaeabacterial protein 
HEF (Meetei et al., 2005). The human ortholog of HEF is 
detected in cells from all FA complementation groups but 
not in cells from a single patient who had been excluded 
from all 11 complementation groups. Sequencing revealed 
biallelic truncations, establishing the twelfth complementa-
tion group, FANCM (Meetei et al., 2005), and identifying the 
responsible gene.
FANCM/HEF contains helicase motifs and a C-terminal 
domain with homology to XPF and MUS81 endonucle-
ases. The latter cleave 3′-overhanging single strands at 
double-strand/single-strand junctions. HEF uses both the 
endonuclease and helicase activities to process stalled 
replication forks, creating DSBs in the process (Komori et 
al., 2004). Despite the fact that the yeast ortholog MPH1 
lacks an endonuclease domain, genetic data implicate 
MPH1 in error-free homologous-recombination-mediated 
repair of DNA damage but not homologous recombination 
itself (Schurer et al., 2004). Interestingly, human FANCM 
also lacks residues identified as critical for endonuclease 
activity of XPF. Deletion of the helicase but not the endo-
nuclease region of chicken FANCM results in exquisite 
sensitivity of the cells to ICL damage and induction of ICL-
induced chromosomal aberrations (Mosedale et al., 2005). 1194 Cell 123, December 29, 2005 ©2005 Elsevier Inc.Notably, in XPF, the converse is true: XPF has inactive heli-
case motifs but an active structure-specific endonuclease 
domain. In view of the homology between these proteins, 
it is intriguing to speculate that both have arisen from the 
same dual-function HEF ancestral helicase/nuclease and 
that each has specialized in one function. Importantly, XPF 
and its essential binding partner ERCC1 are also required 
for tolerance to ICL damage. It will be interesting to deter-
mine whether FANCM forms heterodimers with a partner, 
similar to XPF and MUS81, which form stable complexes 
with ERCC1 and EME1, respectively. Such a presumed 
partner would be a candidate for an additional FA comple-
mentation group.
Knockdown of FANCM expression in human cells by 
siRNA or genetic deletion of the chicken ortholog reduces 
monoubiquitination of FANCD2 in S phase or following 
ICL damage to the cells (Meetei et al., 2005; Mosedale 
et al., 2005), functionally linking FANCM to the FA core 
complex. Biochemical studies confirmed that FANCM is a 
part of the FA core complex, binds to DNA, and is a DNA-
dependent ATPase (Meetei et al., 2005; Mosedale et al., 
2005). Notably, in contrast to its yeast and archaeabac-
terial orthologs, immunoisolated, tagged, recombinant 
FANCM does not have detectable helicase activity in an in 
vitro assay but does have weak translocase-like activity as 
measured by strand displacement from a triplex DNA sub-
strate (Meetei et al., 2005). FANCM is posttranslationally 
modified in cells exposed to ICL damage or the replication 
inhibitor hydroxyurea, an event that does not require the 
FA core complex (Meetei et al., 2005). FANCM mutants in 
chicken DT40 cells are less sensitive to ICL damage than 
FANCC mutants (Mosedale et al., 2005). This suggests 
that FANCM is not an essential component of the FA core 
complex, that it is involved in only a subset of the FA-core-
complex functions, or that there is some functional redun-
dancy with other FANC proteins. These findings add a new 
protein with DNA binding and DNA-metabolizing activity to 
the FA core complex, providing strong evidence that the FA 
pathway participates directly in the sensing of ICLs in DNA 
and the repair and bypass of such lesions.
Speculative Model for the FA Reaction to  
Remove ICLs
The various functions now identified endow the FA pathway 
for the first time with bona fide DNA-metabolizing activi-
ties and point toward this pathway’s participating directly 
in the handling of DNA-ICL damage rather than an indi-
rect role in the cellular response to ICL lesions. Based on 
these new insights, we propose a tentative model for the 
error-prone ICL bypass/repair reaction (see Figure 2). By 
analogy to transcription-coupled repair (in which stalling 
of an elongating RNA polymerase complex by a lesion in 
the transcribed strand of DNA initiates a response involv-
ing removal or displacement of the polymerase to make 
the damage accessible to the nucleotide excision repair 
machinery), we propose that arrest of DNA replication itself 
triggers signaling and repair of the lesion that blocks fork 
progression. A likely early responder to arrested replica-
Figure 2. A Speculative Model of the DNA ICL Repair Pathway Highlighting the Involvement of the FANC Proteins
(1) DNA-damaging agents such as mitomycin C but also endogenous metabolic processes such as lipid peroxidation can cause interstrand crosslinks 
(ICLs). (2) ICLs physically block DNA replication, leading to activation of the ATR kinase, which phosphorylates a number of proteins, including FANCD2 
(inset). Phosphorylated FANCD2 is monoubiquitinated by the FANCL subunit of the FA core complex (circled). This triggers the creation of nuclear foci at 
sites of replication stress consisting of numerous proteins involved in homologous recombination and translesion synthesis. (3) A second consequence of 
blocked replication is the creation of a DSB, which occurs by incision of one of the template strands upstream of the lesion by an endonuclease (depicted 
as scissors). (4) To separate the two template strands, a second incision is required, probably facilitated by the opening of the crosslinked substrate DNA by 
a helicase such as FANCM. (5) To unhook the ICL from the template strand, the second incision must occur on the same strand as the first incision but on 
the other side of the ICL. A likely endonuclease for this incision is ERCC1-XPF, facilitated by the single-stranded binding protein RPA, which dictates which 
strand is cut. (6) The second incision creates a gap and a new 3′ end that can be used to prime DNA synthesis. (7) Gap-filling DNA synthesis, probably by 
an error-prone translesion polymerase, is necessary to restore the damaged template strand. (8) Although these specialized polymerases permit bypass of 
lesions, they frequently insert incorrect bases, creating a mutation at the site of damage. (9) Once the ICL is unhooked and strand integrity is restored, DSB 
repair can occur by template switching, requiring the homologous-recombination machinery. This is initiated by the resection of the broken end to yield a 3′ 
single-strand overhang able to pair with its sister chromatid. (10–11) Repair requires the homologous-recombination machinery, including RAD51, BRCA1, 
BRCA2, PCNA, and RPA. The FANCJ helicase is probably involved at this step. (12) The resolution of Holliday junction recombination intermediates permits 
replication to continue and may or may not result in the formation of a SCE (Figure 1). The unhooked ICL carrying a short oligonucleotide is a likely substrate 
for removal by the nucleotide excision repair system, or, alternatively, spontaneous hydrolysis of the glycosidic bond may detach it from the DNA, leaving a 
mutagenic abasic site. Deubiquitination at the end of S phase turns the pathway off (center). See text for a more detailed explanation.Cell 123, December 29, 2005 ©2005 Elsevier Inc. 1195
tion is the ATR protein kinase signal transducer (Figure 2, 
step 2). One of the many targets of ATR phosphorylation 
is FANCD2 (Pichierri and Rosselli, 2004). The subsequent 
monoubiquitination of FANCD2 by the FANCL subunit of 
the FA core complex (or some other E3 ligase) and trans-
location of FANCD2 to chromatin are dependent upon ATR 
activation (Andreassen et al., 2004). This is consistent with 
the observation that FANCD2 is ubiquitinated during nor-
mal S phase (Taniguchi et al., 2002) and that the level of 
Ub-FANCD2 is further increased in response to ICL dam-
age, ionizing radiation, and replicative stress caused by 
hydroxyurea or aphidicolin, which interfere with normal 
progression of the replication fork (Howlett et al., 2005). 
It is important to note that measurement of steady-state 
levels of DNA damage predict that a genome as large as 
those of mammals contains many spontaneous lesions, a 
significant fraction of which at least transiently arrest DNA 
replication. Endogenous metabolism may even generate 
spontaneous ICLs, for instance from malondialdehyde or 
other byproducts of lipid peroxidation, particularly in the 
liver, providing a possible explanation for the increased 
frequency of liver tumors in FA and predicting accelerated 
aging of this organ, similar to that observed in crosslink-
repair-deficient ERCC1-XPF-deficient mice. Activation of 
ATR by arrested replication machinery also results in phos-
phorylation of histone H2AX, leading to the local genera-
tion of a large number of high-affinity sites for numerous 
proteins involved in DSB processing, including RAD51, 
BRCA2, PCNA, RPA, and other members of the HR repair 
and translesion bypass machineries, and presumably also 
the FA core complex (see Figure 2, step 2). The primary 
function of these foci likely is to increase the local concen-
tration of specific proteins, thereby accelerating catalysis of 
reactions needed for the complex DNA transactions aimed 
at resolving replication stress. ICLs mount a formidable 
challenge because they covalently link both DNA strands, 
hence requiring specialized machinery for resolution. This 
may explain the “raison d’être” of the FA pathway in ver-
tebrate organisms, which contain multiple compartments 
of mitotically active cells for which the FA pathway is par-
ticularly important to prevent replication catastrophe and 
chromosomal aberrations.
For replication bypass of ICLs, the lesion must be 
released from at least one strand of DNA to permit strand 
separation. This necessitates endonucleolytic cleavage of 
one template strand on both sides of the ICL (Figure 2, 
steps 3 and 5). A consequence of these incisions is the 
creation of a DSB (Figure 2, step 4). The identity of the 
endonuclease required for the initial incision, which prob-
ably creates the DSB, is not known. Candidate endonu-
cleases with appropriate substrate specificity include the 
ERCC1-XPF or related MUS81-EME1 complexes. How-
ever, replication-dependent, ICL-induced DSBs occur 
in the absence of either complex (De Silva et al., 2000; 
Dendouga et al., 2005; Niedernhofer et al., 2004), either 
suggesting redundant roles for these endonucleases or 
possibly implicating an as yet unidentified nuclease. A sec-
ond incision of the same strand, on the other side of the 1196 Cell 123, December 29, 2005 ©2005 Elsevier Inc.ICL, unhooks the lesion from that strand of DNA (Figure 2, 
step 5). This incision is likely facilitated by ERCC1-XPF (Nie-
dernhofer et al., 2004). In support of this, ERCC1-XPF-defi-
cient cells are exquisitely sensitive to crosslinking agents, 
and knockout mice show some features reminiscent of 
FA, including bone-marrow failure (Prasher et al., 2005). 
The ERCC1-XPF endonuclease is required for other DNA-
repair processes, most notably nucleotide excision repair 
(NER), which repairs helix-distorting lesions affecting only 
one strand of DNA. However, the ICL sensitivity and knock-
out mouse phenotype are unique among NER mutants, 
implicating a distinct role for ERCC1-XPF in ICL repair 
independent of NER. Importantly, ICL damage causes the 
accumulation of DSBs in replicating ERCC1-XPF-deficient 
cells, consistent with an inability to unhook the crosslink 
(Niedernhofer et al., 2004), a prerequisite for DSB repair via 
homologous recombination.
Endonucleolytic cleavage requires local opening of the 
DNA helix around the lesion, which may be facilitated by 
FANCM, a component of the FA core complex (Figure 2, 
step 4). In addition, the single-strand DNA binding protein 
RPA is also required to direct strand-specific cleavage 
aimed at removing DNA damage by the ERCC1-XPF endo-
nuclease (Figure 2, step 5). RPA is in the vicinity as an inte-
gral component of the replication machinery, which per-
haps needs to be displaced from the site of its arrest. The 
gap resulting from unhooking of the ICL must be filled in 
order to restore the integrity of the template strand (Figure 
2, step 7). This probably requires a specialized translesion 
polymerase since the opposite strand still harbors residual 
damage. Replication past the lesion is expected to be error 
prone (Figure 2, steps 7 and 8), explaining the mutagenic 
character of the FA pathway. It appears paradoxical that 
abolishing this mutagenic FA pathway increases cancer 
predisposition. A likely explanation is that the absence 
of the FA process wreaks more havoc on genome integ-
rity. When any of the preceding steps fail because of a 
FA defect, DSBs result, triggering illegitimate recombina-
tion and radial-structure formation (Figure 1). This affects 
genome stability more than the point mutations caused by 
the FA process. The fact that the repair itself creates muta-
tions illustrates the fundamental problems posed by ICLs 
as this type of damage affects both DNA strands, leaving 
no intact template for repair synthesis.
Once the integrity of the template strand is restored, DSB 
repair and reinitiation of replication are possible. For this to 
occur, the newly synthesized leading strand, interrupted 
by a break, must switch templates, pairing with the now 
intact complementary template strand (Figure 2, step 10). 
This likely requires a helicase to make the template strand 
accessible, for which the FANCJ helicase is a suitable can-
didate. The homologous-recombination machinery is also 
required for joint molecule formation. Resolution of recom-
bination repair intermediates permits reestablishment of 
the replication fork (Figure 2, steps 11 and 12). This prob-
ably involves the BLM-TOPOIIIα, complex, which is also 
associated with the FA core complex (Meetei et al., 2003b). 
The remaining unhooked crosslink on one of the template 
strands may be removed by the nucleotide excision repair 
machinery, resulting in the copying of the mutation into the 
parental strand during gap-filling repair synthesis. Alterna-
tively, when the ICL is no longer stabilized in duplex DNA, 
it may be vulnerable to spontaneous hydrolysis. This would 
release an oligonucleotide carrying the ICL and create a 
highly mutagenic abasic site in the template strand (Figure 
2, step 9). Finally, the FA pathway is turned off by deubiq-
uitination of FANCD2 by USP1, which is activated in late 
S phase (Nijman et al., 2005). In this intricate mechanism 
involving the coordinated action of numerous players, an 
ICL that stops replication can be eliminated at the risk of 
creating point mutations.
Remaining Questions
Obviously, many proteins still await identification in this 
speculative scenario for the repair of ICLs, including the 
endonuclease (or endonucleases), translesion polymerase 
(or polymerases), and chromatin-remodeling proteins 
implied by the model. This leaves plenty of room for dis-
covery of additional complementation groups of FA in the 
future. In vitro reconstitution of the intricate ICL repair and 
lesion bypass reaction poses a significant challenge as, in 
all likelihood, it has been a significant challenge for nature 
to evolve an optimal mechanism to repair ICL damage. 
Akin to the problems encountered by DNA replication, an 
untouched issue is how the transcription machinery deals 
with an ICL that is physically blocking elongation. This is 
particularly interesting because, at least to date, it appears 
that transcription lacks the elaborate translesion machinery 
that is required for lesion bypass during replication. How-
ever, homologous recombination may prove important for 
the resolution of arrested transcription (Aguilera, 2005).
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